Gentian Diagnostics AS

OL:GENT Norway Medical Devices
Market Cap
$53.47 Million
Nkr609.18 Million NOK
Market Cap Rank
#22237 Global
#112 in Norway
Share Price
Nkr39.50
Change (1 day)
+0.00%
52-Week Range
Nkr37.70 - Nkr64.80
All Time High
Nkr86.00
About

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more

Gentian Diagnostics AS - Asset Resilience Ratio

Latest as of December 2025: 40.97%

Gentian Diagnostics AS (GENT) has an Asset Resilience Ratio of 40.97% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
Nkr105.93 Million
Cash + Short-term Investments
Total Assets
Nkr258.54 Million
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Gentian Diagnostics AS's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Gentian Diagnostics AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Nkr105.93 Million 40.97%
Short-term Investments Nkr0.00 0%
Total Liquid Assets Nkr105.93 Million 40.97%

Asset Resilience Insights

  • Very High Liquidity: Gentian Diagnostics AS maintains exceptional liquid asset reserves at 40.97% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Gentian Diagnostics AS Industry Peers by Asset Resilience Ratio

Compare Gentian Diagnostics AS's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
Medical Devices 0.01%
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
Medical Devices 0.26%
Double Medical Technology Inc
SHE:002901
Medical Devices 7.79%
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
Medical Devices 6.64%
Shinhung
KO:004080
Medical Devices 4.17%
UMediC Group Berhad
KLSE:0256
Medical Devices 1.48%
Osang Healthcare Co.,Ltd
KQ:036220
Medical Devices 9.34%
HansBiomed Corporation
KQ:042520
Medical Devices 9.13%

Annual Asset Resilience Ratio for Gentian Diagnostics AS (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Gentian Diagnostics AS.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 36.90% Nkr84.74 Million Nkr229.66 Million +35.79pp
2023-12-31 1.11% Nkr2.01 Million Nkr181.04 Million +0.01pp
2022-12-31 1.11% Nkr2.08 Million Nkr187.79 Million -53.16pp
2021-12-31 54.27% Nkr114.94 Million Nkr211.79 Million -12.88pp
2020-12-31 67.15% Nkr157.99 Million Nkr235.26 Million -8.22pp
2019-12-31 75.37% Nkr171.24 Million Nkr227.18 Million -1.49pp
2018-12-31 76.87% Nkr198.31 Million Nkr257.98 Million +6.21pp
2017-12-31 70.65% Nkr145.00 Million Nkr205.23 Million +10.40pp
2016-12-31 60.25% Nkr74.09 Million Nkr122.96 Million --
pp = percentage points